Navigation Links
High zinc status in lung cells slows growth and induces DNA damage-induced gene expression
Date:2/25/2008

Researchers at the University of Maryland at College Park have discovered that Normal Human Bronchial Epithelial (NHBE) cells cultured in medium with elevated zinc level, at the high end of plasma zinc attainable by oral supplementation, demonstrated inhibition of cell growth, up-regulation of growth arrest and DNA damage-induced gene (Gadd45) mRNA and protein expression, and blockage of G2/M cell cycle progression. The research, published in the March 08 issue of the Experimental Biology and Medicine, demonstrated that the essential nutrient zinc, at elevated physiologic level, is capable of inducing stress responsive genes in the NHBE cells. NHBE cells function as a protective airway barrier and are representative of the cell population during lung tissue transformation and are considered to be progenitor cells for human bronchial cancer.

Gadd45 is ubiquitously expressed in response to genotoxic agents, and is involved in many biological processes related to the maintenance of genomic stability and apoptosis. Over expression of Gadd45 was found to induce G2/M cell cycle arrest. The importance of Gadd45 in G2/M regulation was further supported by findings of the inability of cells from Gadd45 knockout mice to arrest at the G2/M phase after exposure to UV radiation. In addition, a functional association between stress-activated mitogen-activated protein kinase p38 pathway and Gadd45 in response to environmental stresses has been established in past studies. Moreover, the dependence of Gadd45 induction for the normal function of the tumor suppressor gene p53, which plays an important role in the maintenance of genomic fidelity by controlling cell cycle checkpoints and apoptotic processes following cell exposure to genotoxic stress, is well established. Furthermore, in response to DNA damage, Gadd45 was found to contribute to the stability of p53.

The research team, led by David K. Y. Lei, a professor of Nutrition, and Rita S. M. Shih, a recent doctoral graduate, designed the study to determine the influence of zinc status on Gadd45 expression and cell cycle progression in NHBE cells, and to decipher the molecular mechanism(s) exerted by the suppression of Gadd45 expression on cell growth and cell cycle progression in this normal human cell type.

Inhibition of cell growth, up-regulation of Gadd45 mRNA and protein expression, and blockage of G2/M cell cycle progression were observed in NHBE cells cultured in high zinc medium - the zinc supplemented (ZS) cells said Lei. The siRNA-mediated knocking down of Gadd45 was found to relieve G2/M blockage in ZS cells, which indicated that the blockage was Gadd45 dependent. Moreover, the enhanced phosphorylation of p38 and p53 (ser15) observed in ZS cells was normalized after suppression of Gadd45 by siRNA, implicating that the enhanced phosphorylation of these proteins was Gadd45 dependent. Thus, the researchers demonstrated for the first time that an elevated zinc status modulated the p53 and p38 signal transduction pathways to produce a delay at G2/M during cell cycle progression in NHBE cells.

Lei says the use of normal human cell types to evaluate the influence of nutrients and bioactive plant materials on the expression of stress responsive genes and cell cycle progression is a rapid and valuable approach to identify potential targets and provide mechanistic data. However, the applicability of these in vitro mechanistic data would require confirmation by detailed in vivo studies

Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine said This study on the molecular and cellular response of NHBE cells to a high zinc challenge may have important implications for conditions such as industrial exposure and extensive usage of zinc supplementation in animal production and in humans. He further stated The use of molecular and cellular approaches to address problems in nutritional sciences is the type of interdisciplinary study that the new Experimental Biology and Medicine is interested in publishing.


'/>"/>

Contact: David K.Y. Lei
dlei@mail.umd.edu
301-405-2143
Society for Experimental Biology and Medicine
Source:Eurekalert

Related medicine news :

1. TransUnion Addresses Ohio Attorney Generals Concerns Surrounding Non-Profit Tax-Exempt Status
2. Timely Cancer Diagnosis Linked to Insurance Status
3. Major study links insurance status to advanced stage in multiple cancers
4. Landmark Articles Published by QualityMetric Scientists Report Improvements in Short Form Health Status Measures and Establish Criteria for Future Development
5. Ocera Therapeutics Receives Orphan Drug Status for AST-120 for Pouchitis
6. Insurance status linked to cancer outcomes
7. Alzheimers Foundation of America Awards Excellence in Dementia Care Status to First Adult Day Center, More Long-Term Care Settings
8. Isis Announces ISIS 333611 Granted Orphan Drug Status for Treatment of ALS
9. TREANDA New Drug Application for the Treatment of Chronic Lymphocytic Leukemia Granted Priority Review Status by FDA
10. Unstable housing status increases the risk of HIV transmission
11. Global view shows link between endometrial cancer and vitamin D status
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 30, 2016 , ... World Patent Marketing ... Up Springboard, an automotive invention that improves the storage features of a pick ... billion," says Scott Cooper, CEO and Creative Director of World Patent Marketing. "Over ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... , announces the addition Onnit brand Alpha BRAIN and New Mood Daily-Stress Formula ... brain and mood optimization products to the store is just one more way ...
(Date:4/29/2016)... ... April 29, 2016 , ... The White House announced ... loans, more information about their loan terms and accounts, and more protections for ... including federal and private loans, has reached $1.3 trillion, with 43 million Americans ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Wharton ... $30,000 Perlman Grand Prize of the 2016 Wharton Business Plan Competition —as ... People’s Choice Award, and the Committee Award for Most ‘Wow Factor,’ making them ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. Robert Mondavi, one of the ... smiles. Cosmetic dentistry is a fast-growing field as more patients are discovering the many ... learn more about the options currently available to them and which ones might work ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... Oasmia Pharmaceutical AB (NASDAQ: ... new generation of drugs within human and veterinary ... Paclical/Apealea in the Phase III study that included ... cancer. These preliminary results showed non-inferiority between the ... versus Taxol in combination with carboplatin. In fact, ...
(Date:4/27/2016)... At the Sachs CEO forum ... Phase 2 clinical study of its lead drug candidate, ... implantation (CI) surgery. This large, placebo-controlled, double-blind, phase 2 ... and France . STR001 ... time of surgery. "Despite advances in cochlear implant technology, ...
(Date:4/26/2016)... April 26, 2016 US demand for ... expand 4.9 percent annually to $27.6 billion in ... facilities to decrease rates of healthcare-associated infections (HAIs) ... equipment, and services.  Although declining, the overall rate ... targeted levels set by the CDC.  Recent statistics ...
Breaking Medicine Technology: